ReviewFrontiers in pharmacology2024
Therapeutic evolution in HR+/HER2- breast cancer: from targeted therapy to endocrine therapy.
Lu-Qi Cao et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
21 papers cite it
this paperpooled itcites it